Mutares Reports Record Profit as Dilution and Debt Woes Weigh on Share Price

Mutares posts record €130M profit but shares hit 52-week low amid debt covenant breach, dilution, and loss of founder veto power.

Mutares is delivering a tale of two narratives. The Munich-based holding company posted a record net profit of €130.4 million for 2025 on revenues of roughly €6.5 billion, yet its shares are plumbing fresh depths. The disconnect between operational performance and market sentiment has rarely been starker.

The stock closed at €23.60 on Friday, a new 52-week low and a 26% monthly decline. That puts the equity well below the €24.50 placement price of the 4.2 million new shares issued in the recent capital raise, which generated gross proceeds of around €105 million. Those new shares begin trading on Tuesday, adding further supply to a market already digesting the dilution.

Founders Lose Their Veto

The capital increase has reshaped the company’s ownership structure. The founding Laik family’s voting stake has been diluted below the 25% threshold, stripping them of the blocking minority they previously held on key shareholder resolutions. While the family retains a significant passive holding, the loss of veto power marks a notable shift in corporate governance.

Debt Covenant Breach Triggers Bondholder Talks

The share price weakness reflects more than just dilution. Mutares breached a key leverage covenant at the turn of the year, forcing management to seek a waiver from bondholders through mid-2026. A new amortisation schedule has been agreed: starting in the second quarter, the company will buy back regular tranches of its outstanding bond, aiming to reduce the total volume by a three-digit million-euro amount by year-end.

Cash Deployment and Portfolio Reshuffling

The bulk of the fresh equity is earmarked for the US expansion, where Mutares sees attractive acquisition opportunities. The remainder will shore up the balance sheet. In Europe, the portfolio is being restructured: the sale of the inTime Group is underway, and the integration of two Magna divisions is progressing. In the second half, Mutares expects regulatory clearance for a multi-million-euro acquisition from chemicals group SABIC.

Analysts Stay Bullish Despite the Sell-Off

Research houses remain largely unfazed by the near-term turbulence. Warburg Research rates the stock a “buy” with a €46.00 target, while Jefferies maintains its “buy” rating at a €37.00 target. Both point to the proven business model and a string of successful exits this year, including Kalzip, Relobus, and the inTime Group.

Key Dates Ahead

Tuesday brings two major events: the release of the audited full-year results and the start of trading for the new shares. Management will host a webcast to discuss strategy, with the dividend proposal and the 2026 outlook taking centre stage. Mutares traditionally pays a base dividend plus a bonus; last year’s payout was €2.00 per share. Market participants expect concrete proposals on the new distribution level.

The first-quarter numbers are due on May 12. With the stock trading at a discount to the capital raise price, a strong outlook could provide the catalyst needed to reverse the downward trend.